Overview
Status
Active
Registry date
2019-12-18
Share capital
5 000,00 PLN
Registered address
ul. Królowej Jadwigi 148A/1a, 30-212 Kraków, Poland
Electronic delivery address
AE:PL-96740-22937-VTCGI-28
Financials
Revenue history (in k)
Filing timeliness
3 of 6 financial statements were filed late (the longest delay 322 days for 2021).
- 202509/07/2026
- 202413/06/2025
- 202316/07/2024
- 202223/06/2023
- 202102/06/2023
- 202007/03/2022
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 668.13kMedianUSD 917.74kAverageUSD 25.73m
Net profit
This companyUSD -143.02kMedianUSD 14.44kAverageUSD 2.75m
Operating costs
This companyUSD 679.80kMedianUSD 860.03kAverageUSD 21.34m
Assets
This companyUSD 147.44kMedianUSD 883.09kAverageUSD 31.39m
Industry
Authorized Representatives
Andrzej Charewicz – Management Board Member
Tomasz Gomulec – President of the Management Board
Janusz Piotr Sikora – Management Board Member
Piotr Konop – Attorney-in-fact (sole)
Manner of representation
The company’s declarations of will may be made by two members of the company’s management board acting jointly, or by one member of the company’s management board together with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Janusz Piotr Sikoraage 60 | 10 | $135.06 | 10% |
| 90 | $1,215.56 | 90% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2020-01-04.
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A. | $37,103,878.54 | biomed.pl | ||
| Fagronsp. z o.o. | $21,715,187.73 | fagron.pl | ||
| Krakowskie Zakłady Zielarskie Herbapol w KrakowieS.A. | $7,294,338.51 | herbapol.krakow.pl | ||
| Biomarsp. z o.o. | $909,113.28 | biomar.pl | ||
| Przedsiębiorstwo Farmaceutyczne Leki Natury Tadeusz Polańskisp. z o.o. | $893,738.50 | lekinatury.pl | ||
| Human BiomeS.A. | $888,361.19 | human-biome.com | ||
| Zeptor Polskasp. z o.o. | $748,374.79 | zeptor.pl | ||
| DR Andresp. z o.o. | $453,987.42 | drandre.pl | ||
| F1 PharmaS.A. | $272,113.66 | f1pharma.pl | ||
| Zakład Farmaceutyczny Amarasp. j. | $0.00 | amara.pl |
FAQ
The main business activity of Neotac Pharma focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on December 18, 2019.
The headquarters is located at: ul. Królowej Jadwigi 148A, 30-212 Kraków.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
The company reported a revenue of $470,517 in 2024, which is an increase of 4.3% compared to 2023.
Yes, in 2024 the company was profitable, achieving a net profit of $13,032, meaning the company decreased its profit by 59.4%.
Last updated: 2026-07-15
